Given the high discontinuation rates of oral SMO antagonists, a topical inhibitor, patidegib, has also been trialed with reduced disease burden in patients with Gorlin syndrome [66]. This evidence concerns the gene SMO and nevoid basal cell carcinoma syndrome.